MCF Advisors LLC Sells 1,587 Shares of Johnson & Johnson (NYSE:JNJ)

MCF Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,181 shares of the company’s stock after selling 1,587 shares during the period. MCF Advisors LLC’s holdings in Johnson & Johnson were worth $2,243,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of JNJ. Keener Financial Planning LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $40,000. WFA Asset Management Corp grew its position in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after buying an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $44,000. Disciplined Equity Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $45,000. Finally, Grayhawk Investment Strategies Inc. grew its position in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after buying an additional 259 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.2 %

Shares of JNJ opened at $146.16 on Friday. The company has a market capitalization of $351.76 billion, a P/E ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The business’s 50 day simple moving average is $148.14 and its 200-day simple moving average is $154.06.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the previous year, the company posted $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on JNJ shares. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.